Read by QxMD icon Read

Metformin Aging

Daniala L Weir, Michal Abrahamowicz, Marie-Eve Beauchamp, Dean T Eurich
AIMS: Observational studies evaluating the safety and effectiveness of metformin have yielded ambiguous results, possibly due to how time-varying drug exposure was modeled. Therefore, our objective was to re-evaluate the association between metformin use and heart failure (HF) exacerbation in patients with type 2 diabetes (T2D) and pre-existing HF using alternative exposure models. MATERIALS AND METHODS: We analyzed data for patients with T2D and incident HF from a national U...
June 23, 2018: Diabetes, Obesity & Metabolism
Liv Guro Engen Hanem, Rønnaug Ødegård, Eszter Vanky
No abstract text is available yet for this article.
June 20, 2018: Journal of Clinical Endocrinology and Metabolism
Carolina Castillo-Castro, Camilo Gonzalez-Velazquez, Rene Rodriguez-Gutierrez
No abstract text is available yet for this article.
June 20, 2018: Journal of Clinical Endocrinology and Metabolism
Sadanori Okada, Takeshi Morimoto, Hisao Ogawa, Mio Sakuma, Chisa Matsumoto, Hirofumi Soejima, Masafumi Nakayama, Naofumi Doi, Hideaki Jinnouchi, Masako Waki, Izuru Masuda, Yoshihiko Saito
OBJECTIVE: This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. RESEARCH DESIGN AND METHODS: This study was a posttrial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial. Participants in the JPAD trial (2,536 Japanese patients with type 2 diabetes and without preexisting cardiovascular disease) were randomly allocated to receive aspirin (81 or 100 mg daily) or no aspirin...
June 16, 2018: Diabetes Care
Stefan Korsatko, Lene Jensen, Martina Brunner, Stefanie Sach-Friedl, Maja D Tarp, Anders G Holst, Simon R Heller, Thomas R Pieber
AIMS: To investigate effects of semaglutide versus placebo on glucagon and other counterregulatory hormones during hypoglycaemia in type 2 diabetes. METHODS: This double-blind, placebo-controlled, single-centre trial randomised 38 men and women (treated only with metformin) 1:1 to two 12-week crossover periods of once-weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure. The primary endpoint was change in glucagon concentration from target plasma glucose level 5...
June 12, 2018: Diabetes, Obesity & Metabolism
Jing Zhao, Xiaoyan Liu, Wenhua Zhang
OBJECTIVE: This study was to analyze the efficacy of metformin intervention in preventing gestational diabetes mellitus (GDM). METHODS: A systematic review and meta-analysis of clinical trials or observational studies of metformin intervention in preventing symptoms of GDM during pregnancy were performed. Medline, Embase, and Cochrane Library were searched through to now. The main evaluated primary outcomes were incident of GDM, miscarriage, preterm delivery, and neonatal mortality...
June 11, 2018: Experimental and Clinical Endocrinology & Diabetes
Dur Muhammad Khan, Asif Jamil, Fawad Ahmad Randhawa, Nasir Farooq Butt, Uzma Malik
OBJECTIVE: To study the efficacy of oral vitamin D in improving glycaemic control of patients with type 2 diabetes by reducing glycated haemoglobin levels. METHODS: This randomised control trial was carried out at Mayo Hospital, Lahore, from February 5 to August 5, 2016, and comprised type 2 diabetes patients aged 40-70 years visiting the outpatient clinics. They were randomly divided into two groups by using the lottery method. Group A received oral vitamin D along with metformin and group B received metformin only...
May 2018: JPMA. the Journal of the Pakistan Medical Association
Hyo-Joong Won, Gokyung Chung, Kyeong Ju Lee, Eunkyung Lee, Soonjoo Son, Soyoung Choi, Seon Cheol Park, Yu Jeung Lee
OBJECTIVE: The administration of the usual dosage of medication in elderly patients with renal impairment can cause adverse drug reactions due to patients' decreased renal function. Using retrospective prescription analysis, in a teaching hospital, this study aimed to evaluate medication dosing errors in elderly patients with renal impairment and the risk factors for these dosing errors. MATERIALS AND METHODS: This retrospective study included elderly patients with a creatinine clearance of 59 mL/min or less who were hospitalized in a teaching hospital between July 1, 2015, and September 30, 2015...
June 8, 2018: International Journal of Clinical Pharmacology and Therapeutics
Cornelia Bala, Adriana Rusu, Dana Mihaela Ciobanu, Anca Elena Craciun, Gabriela Roman
Purpose: The objective of this study was to examine the association between insulin dose and high-sensitivity C-reactive protein (hsCRP), nitrotyrosine, and pentraxin 3 in patients with insulin-treated type 2 diabetes. Patients and methods: Eighty patients with type 2 diabetes treated with insulin for >6 months and with stable insulin doses (±10%) within 3 months before inclusion were enrolled in this study. Medical history, including use of insulin and insulin doses, concomitant diseases and medication, and anthropometric and routine biochemical parameters were collected for each patient...
2018: Therapeutics and Clinical Risk Management
Serkan Bodur, Ozgur Dundar, Mine Kanat-Pektas, Mehmet Ferdi Kinci, Levent Tutuncu
OBJECTIVE: This study was designed to evaluate the effects of 3 mg drospirenone/30 μg ethinyl estradiol (OC) alone or combined with 1700 mg metformin on metabolic risk factors. MATERIALS AND METHODS: In this randomized, prospective, controlled study, 87 non-obese (18-30 BMI) women of reproductive age (18-39) with polycystic ovary syndrome (PCOS) were assigned to control (n = 17), OC (n = 21), combination (n = 20) and metformin (n = 29) therapy groups...
June 2018: Taiwanese Journal of Obstetrics & Gynecology
Slagjana Simeonova-Krstevska, Milco Bogoev, Ksenija Bogoeva, Elizabeta Zisovska, Igor Samardziski, Valentina Velkoska-Nakova, Vesna Livrinova, Irena Todorovska, Aneta Sima, Vesna Blazevska-Siljanoska
AIM: Aim of the study was to compare outcomes of pregnancy in gestational diabetes mellitus (GDM) treated with metformin, insulin, or diet. MATERIAL AND METHODS: The study included 48 women with GDM treated with metformin, 101 with insulin, and 200 women on a diet from the Outpatient Department of Endocrinology and University Clinic of Obstetrics and Gynecology in Skopje. RESULTS: The groups were comparable in age, smoking cigarettes and positive family history of diabetes...
May 20, 2018: Open Access Macedonian Journal of Medical Sciences
Alexandra M V Wennberg, Clinton E Hagen, Kelly Edwards, Rosebud O Roberts, Mary M Machulda, David S Knopman, Ronald C Petersen, Michelle M Mielke
OBJECTIVE: To determine the cross-sectional and longitudinal associations between diabetes treatment type and cognitive outcomes among type II diabetics. METHODS: We examined the association between metformin use, as compared to other diabetic treatment (ie, insulin, other oral medications, and diet/exercise) and cognitive test performance and mild cognitive impairment (MCI) diagnosis among 508 cognitively unimpaired at baseline type II diabetics enrolled in the Mayo Clinic Study of Aging...
June 5, 2018: International Journal of Geriatric Psychiatry
Janielle da Silva Melo da Cunha, Tamaeh Monteiro Alfredo, Jéssica Maurino Dos Santos, Valter Vieira Alves Junior, Luiza Antas Rabelo, Emerson Silva Lima, Ana Paula de Araújo Boleti, Carlos Alexandre Carollo, Edson Lucas Dos Santos, Kely de Picoli Souza
Diabetes has emerged as one of the largest global epidemics; it is estimated that by 2035, there will be 592 million diabetic people in the world. Brazilian biodiversity and the knowledge of traditional peoples have contributed to the treatment of several diseases, including diabetes. Apis mellifera bee tea is used by indigenous Brazilians to treat diabetes, and this traditional knowledge needs to be recorded and studied.The objective of this study was to record the use and to evaluate the antioxidant, antihyperglycemic, and antidiabetic activity of Apis mellifera bee tea, which is used by the Guarani and Kaiowá indigenous people for the treatment of diabetes...
2018: PloS One
Agnieszka Zawada, Dariusz Naskręt, Paweł Burchardt, Paweł Niedźwiecki, Stanisław Piłaciński, Bogna Wierusz-Wysocka, Marian Grzymisławski, Dorota Zozulińska-Ziółkiewicz
INTRODUCTION Bad nutritional habits and administration of insulin in supraphysiological doses lead to the development of insulin resistance and poor metabolic control in patients with type 1 diabetes. Accumulation of visceral fat is the main cause of the decrease in insulin sensitivity. OBJECTIVES We aimed to evaluate changes in anthropometric parameters, indirect measures of insulin resistance, and safety of treatment with metformin added to intensive insulin therapy in patients with type 1 diabetes and excess body fat...
May 30, 2018: Polish Archives of Internal Medicine
Benjamin Lazarus, Aozhou Wu, Jung-Im Shin, Yingying Sang, G Caleb Alexander, Alex Secora, Lesley A Inker, Josef Coresh, Alex R Chang, Morgan E Grams
Importance: Approximately 1 million patients in the United States with type 2 diabetes mellitus and mild-to-moderate kidney disease do not receive guideline-directed therapy with metformin. This may reflect uncertainty regarding the risk of acidosis in patients with chronic kidney disease. Objective: To quantify the association between metformin use and hospitalization with acidosis across the range of estimated glomerular filtration rate (eGFR), accounting for change in eGFR stage over time...
June 4, 2018: JAMA Internal Medicine
Arkadiusz Retwiński, Marcin Kosmalski, Marisa Crespo-Leiro, Aldo Maggioni, Grzegorz Opolski, Piotr Ponikowski, Lech Poloński, Ewa Jankowska, Jerzy Drzewoski, Jarosław Drożdż
BACKGROUND: Metformin (MET) is one of antihyperglycaemic substances that reduces risk of major cardiovascular events, including fatal ones. Although it is formally contraindicated in moderate and severe functional stages of heart failure (HF), it is commonly used in patients with concomitant type 2 diabetes mellitus (T2DM). AIM: Evaluation of the effect of MET and T2DM on total mortality and hospitalization rates in patients with HF. METHODS: 1030 adult patients (>18 years) with HF from the Polish section of HF Long-Term Registry were included in years 2011-2014 into this retrospective analysis...
June 4, 2018: Kardiologia Polska
E Lasalvia-Prisco, C Dau, J Vázquez, P Goldschmidt, F Galmarini
Clinical records from individuals followed for 5 years, 2000 to 2005, were reviewed. They were distributed in 3 cohorts of ages ranging from 51 to 60, 61 to 70, and 71 to 80 years, respectively. Each cohort included 2 groups of patients with diabetes type 2, one group treated with Metformin 850 mg/day, and the other one without pharmacological treatment. In all groups, for each individual, the mean variation of glycosylated hemoglobin, ferritin, lymphocyte count, total and subpopulations, was determined in blood using the measurement at the beginning and at the end of the 5-year follow-up...
2018: Advances in Gerontology, Uspekhi Gerontologii
Mark A Hilado, Ruvdeep S Randhawa
BACKGROUND: Proopiomelanocortin (POMC) is a complex polypeptide that produces a variety of biologically active substances via cleavage in a tissue-specific manner [Challis BG, Millington GW. Proopiomelanocortin deficiency. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle, 1993-2018], yielding several products including adrenocorticotrophic (ACTH) and melanocyte stimulating hormones (MSH). These peptides have roles in the regulation of food intake, energy homeostasis, adrenal steroidogenesis, melanocyte stimulation and immune modulation...
June 2, 2018: Journal of Pediatric Endocrinology & Metabolism: JPEM
Giuseppina Catanzaro, Zein Mersini Besharat, Martina Chiacchiarini, Luana Abballe, Claudia Sabato, Alessandra Vacca, Paola Borgiani, Francesco Dotta, Manfredi Tesauro, Agnese Po, Elisabetta Ferretti
The circulating microRNAs (miRNAs) associated with type 2 diabetes (T2D) in elderly patients are still being defined. To identify novel miRNA biomarker candidates for monitoring responses to sitagliptin in such patients, we prospectively studied 40 T2D patients (age > 65) with HbA1c levels of 7.5-9.0% on metformin. After collection of baseline blood samples ( t 0 ), the dipeptidyl peptidase-IV (DPP-IV) inhibitor (DPP-IVi) sitagliptin was added to the metformin regimen, and patients were followed for 15 months...
2018: International Journal of Endocrinology
Alexandro J Martagón, Omar Yaxmehen Bello-Chavolla, Olimpia Arellano-Campos, Paloma Almeda-Valdés, Geoffrey A Walford, Ivette Cruz-Bautista, Donají V Gómez-Velasco, Roopa Mehta, Liliana Muñoz-Hernández, Magdalena Sevilla-González, Tannia L Viveros-Ruiz, María Luisa Ordoñez-Sánchez, Rosario Rodríguez-Guillen, Jose C Florez, María Teresa Tusié-Luna, Carlos A Aguilar-Salinas
OBJECTIVE: To assess if an ethnic-specific variant (p.E508 K) in the maturity-onset diabetes of the young (MODY) gene hepatocyte nuclear factor-1α ( HNF1A ) found in Mexicans is associated with higher sensitivity to sulfonylureas, as documented in patients with MODY3. RESEARCH DESIGN AND METHODS: We recruited 96 participants (46 variant carriers and 50 age- and sex-matched noncarriers). Response to glipizide (one 2.5-5.0-mg dose), metformin (four 500-mg doses), and an oral glucose challenge was evaluated using a previously validated protocol...
May 29, 2018: Diabetes Care
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"